Parexel allies with Proteome to boost biomarker offering

By Nick Taylor

- Last updated on GMT

Related tags Pharmacology Clinical trial Contract research organization

Parexel has formed an alliance with Proteome Sciences to enhance its biomarker capabilities, allowing it to help clients make earlier assessments of new compounds in development.

Contract research organisations (CRO) have been bolstering their biomarker capabilities to help clients decide at an early stage which therapeutic candidates to continue developing. Demand for this insight has increased as a result of cost cutting and need to reduce Phase II attrition.

We believe that the current regulatory requirements for biomarkers in drug development and diagnostics coupled with the need for fast, flexible and cost effective workflows have meant that specialist services will be increasingly required​”, said Christopher Pearce, CEO of Proteome.

Parexel is using Proteome Sciences’ PS Biomarker Services to meet this demand. The system provides mass spectrometric and pharmacokinetic assays for protein and peptide compounds.

Proteome has an ISO 9001:2008 facility in Frankfurt, Germany which is “designed to provide expert protein biomarker discovery and validation and for the development of rapid mass spectrometric-based assays​”, Pearce added.

This provides Parexel with the capacity and expertise needed to select the relevant biomarkers for their developmental programmes. Results from the biomarker work will then be interpreted to determine the biological activity and safety profile of a therapeutic candidate.

Early phase offering

The alliance strengthens Parexel’s early phase offering, which includes a broad portfolio of biomarkers and non-routine laboratory analysis. Using this infrastructure Parexel can offer biomarkers in a range of therapeutic fields, including oncology, neurology and cardiology.

Furthermore, the CRO offers cellular and soluble biomarker analysis. This is supported by bioanalytical services for quantitative and qualitative drug, metabolite and biomarker analysis in a variety of matrices.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more